Jump to Navigation
Banner

Overview

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.

 

Recent News
Jan 11, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. To Our Shareholders, During the course of 2016, our primary mission was the...

Dec 21, 2016

Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Last week, President Obama signed the 21st Century Cures Act into law. The $6.3...

View all News Releases

Events
Thursday, November 10, 2016
4:30pm EST
Tuesday, October 18, 2016
3:30pm PDT

View All Events


print email

Back to Top


Site 'Subpage' Navigation:

Investor Relations

NASDAQAEMD
Investor Contact

Aethlon Medical, Inc.
858-459-7800

Back to Top